Prognostic value of matrix metalloproteinase-2 (MMP-2) expression in endometrial endometrioid adenocarcinoma

Anticancer Research

Volumn 25, Issue 6 B, 2005, Pages 4101-4105

  Talvensaari Mattila, Anne ^a   Santala, Markku ^a,b   Soini, Ylermi ^a   Turpeenniemi Hujanen, Taina ^a  

^a UNIVERSITY OF OULU   (Finland)

^b Box 24 ^*  (Finland)

Author keywords

Endometrial cancer; Matrix metalloproteinases; MMP 2; Prognostic factors

Indexed keywords

GELATINASE A; ZINC DERIVATIVE;

ADULT; AGED; ANTIBODY SPECIFICITY; ARTICLE; CANCER GRADING; CANCER INVASION; DIAGNOSTIC VALUE; ENDOMETRIUM CARCINOMA; FEMALE; FINLAND; FOLLOW UP; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; METASTASIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION;

AGED; CARCINOMA, ENDOMETRIOID; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MATRIX METALLOPROTEINASE 2; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PROGNOSIS; SURVIVAL RATE;

EID: 27944432021     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Davidson B, Goldberg I, Gotlieb WH, Kopolovic J, Ben-Baruch G, Nesland JM, Berner A, Bryne M and Reich R: High levels of MMP-2, MMP-9, MT1-MMP and TIMP-2 mRNA correlate with poor survival in ovarian carcinoma. Clin Exp Metastasis 17: 799-808, 1999.
2. Sakata K, Shigemasa K, Nagai N and Ohama K: Expression of matrix metalloproteinases (MMP-2, MMP-9, MT1-MMP) and their inhibitors (TIMP-1, TIMP-2) in common epithelial tumors of the ovary. Int J Oncol 17: 673-681, 2000.
3. Curran S and Murray GI: Matrix metalloproteinases in tumour invasion and metastasis. J Pathol 189: 300-308, 1999.
4. Väisänen A, Kallioinen M, Taskinen PJ and Turpeenniemi-Hujanen T: Prognostic value of MMP-2 immunoreactive protein (72 kD type IV collagenase) in primary skin melanoma. J Pathol 186: 51-58, 1998.
5. Hofmann UB, Westphal JR, Waas ET, Zendman AJW, Cornelissen IMHA, Ruiter DJ and van Muijen GNP: Matrix metalloproteinases in human melanoma cell lines and xenografts: increased expression of activated matrix metalloproteinase-2 (MMP-2) correlates with melanoma progression. Br J Cancer 81: 774-782, 1999.
6. Announcements. FIGO stages - 1988 revision: Gynecol Oncol 35: 125-127, 1989.
7. Autio-Harmainen H, Hurskainen T, Niskasaari K, Höyhtyä M and Tryggvason K: Simultaneous expression of 72 kilodalton type IV collagenase and type IV collagen a1(IV) chain genes by cells of early human placenta and gestational endometrium. Lab Invest 67: 191-200, 1992.
8. Autio-Harmainen H, Karttunen T, Hurskainen T, Höyhtyä M, Kauppila A and Tryggvason K: Expression of 72 kDa type IV collagenase in benign and malignant ovarian tumors. Lab Invest 69: 312-321, 1993.
9. Margulies IMK, Höyhtyä M, Evans C, Stracke ML, Liotta LA and Stetler-Stevenson WG: Urinary type IV collagenase elevated levels are associated with bladder transitional cell carcinoma. Cancer Epidemiol Biomarkers Prev 1: 467-474, 1992.
10. Höyhtyä M, Fridman R, Komarck D, Porter-Jordan K, Stetler-Stevenson WG, Liotta LA and Liang CM: Immunohistochemical localization of matrix metalloproteinase 2 and its specific inhibitor TIMP-2 in neoplastic tissue with monoclonal antibodies. Int J Cancer 54: 500-505, 1994.
11. Gofflin F, Frankenne F, Beliard A, Perrier S, Hauterive D, Pignon MR, Geenen V and Foidart JM: Human endometrial epithelial cells modulate the activation of gelatinase A by stromal cells Gynecol Obstet Invest 53: 105-111, 2002.
12. Cork BA, Tuckerman EM, Li TC and Laird SM: Expression of interleukin (IL)-11 receptor by the human endometrium in vivo and effects of IL-11, IL-6 and LIF on the production of MMP and cytokines by human endometrial cells in vitro. Mol Hum Reprod 8: 841-848, 2002.
13. Zhang J and Salamonsen LA: In vivo evidence for active matrix metalloproteinases in human endometrium supports their role in tissue breakdown at menstruation. J Clin Endocrinol Metab 87: 2346-2351, 2002.
14. Brinckerhoff CE, Rutter JL and Benbow U: Interstitial collagenases as markers of tumor progression. Clin Cancer Res 6: 4823-4830, 2000.
15. Väisänen A, Tuominen H, Kallioinen M and Turpeenniemi-Hujanen T: Matrix metalloproteinase-2 (72 kD type IV collagenase) expression occurs in the early stage of human melanocytic tumour progression and may have a prognostic value. J Pathol 180: 283-289, 1996.
16. Väisänen A, Kallioinen M, von Dickhoff K, Laatikainen L, Höyhtyä M and Turpeenniemi-Hujanen T: Matrix metalloproteinase-2 (MMP-2) immunocreactive protein. A new prognostic marker in uveal melanoma? J Pathol 188: 56-62, 1999.
17. Talvensaari-Mattila A, Pääkkö P, Höyhtyä M, Blanco-Sequeiros G and Turpeenniemi-Hujanen T: Matrix-metalloproteinase-2 immunocreactive protein, a marker of aggressiveness in breast carcinoma. Cancer 83: 1153-1162, 1998.
18. Talvensaari-Mattila A, Apaja-Sarkkinen M, Höyhtyä M, Westerlund A, Puistola U and Turpeenniemi-Hujanen T: Matrix metalloproteinase -2 immunoreactive protein appears early in cervical epithelial dedifferentiation. Gynecol Oncol 72: 306-311, 1999.
19. Talvensaari-Mattila A, Pääkkö P and Turpeenniemi-Hujanen T: MMP-2 positivity and age less than 40 years increases the risk for recurrence in premenopausal patients with node-positive breast carcinoma. Breast Cancer Res Treat 58: 287-293, 1999.
20. Talvensaari-Mattila A, Pääkkö P, Blanco-Sequeiros G and Turpeenniemi-Hujanen T: Matrix metalloproteinase-2 (MMP-2) is associated with the risk for a relapse in postmenopausal patients with node-positive breast carcinoma treated with antiestrogen therapy. Breast Cancer Res Treat 65: 55-56, 2001.
21. Hirvonen R, Talvensaari-Mattila A, Pääkkö P and Turpeenniemi-Hujanen T: Matrix metalloproteinase-2 (MMP-2) in T(1-2)N0 breast carcinoma. Breast Cancer Res Treat 77: 85-91, 2003.
22. Monteagudo C, Merino MJ, San-Juan J, Liotta LA and Stetler-Stevenson WG: Immunohistochemical distribution of type IV collagenase in normal, benign and malignant breast tissue. Am J Pathol 136: 585-589, 1990.
23. Levy AT, Cioce V, Sobel ME, Garbisa S, Grigioni WF and Liotta LA: Increased expression of the 72 kDa type IV collagenase in human colonic adenocarcinoma. Cancer Res 51: 439-444, 1991.
24. Polette M, Gilbert N, Stas I, Nawrocki B, Noel A, Remade A, Stetler-Stevenson WG, Birembaut P and Foidart M: Gelatinase A expression and localization in human breast cancers. An in situ hybridization study and immunohistochemical detection using confocal microscopy. Wirchows Arch 424: 641-645, 1994.
25. Tryggvason K, Höyhtyä M and Pyke C: Type IV collagenases in invasive tumours. Breast Cancer Res Treat 24: 209-218, 1994.
26. Visscher DW, Höyhtyä M, Ottosen SK, Liang C-M, Sarkar FH, Crissman D and Fridman R: Enhanced expression of tissue inhibitor of metalloproteinase-2 (TIMP-2) in the stroma of breast carcinomas correlates with tumor recurrence. Int J Cancer 59: 339-344, 1994.
27. Foidart JM: Stromal proteases in the progression of breast cancer. Bull Mem Acad R Med Belg 152: 229-235, 1997.
28. Lee KS, Rha SY, Kim SJ, Roh JK, Kim BS and Chung HC: Sequential activation and production of matrix metalloproteinase-2 during breast cancer progression. Clin Exp Metastasis 14: 512-519, 1996.
29. Moser PL, Hefler L, Tempfer C, Neunteufel W, Kieback DG and Gitsch G: Immunohistochemical detection of matrix metalloproteinases (MMP) 1 and 2, and tissue inhibitor of metalloproteinase 2 (TIMP 2) in stage I and II endometrial carcinoma. Anticancer Res 19: 2365-2367, 1999.
30. Davidson B, Goldberg I, Kopolovic J, Lerner-Geva L, Gotlieb WH, Ben-Baruch G and Reich R: MMP-2 and TIMP-2 expression correlates with poor prognosis in cervical carcinoma - a clinicopathologic study using immunohistochemistry and mRNA in situ hybridization. Gynecol Oncol 73: 372-382, 1999.
31. Di Nezza LA, Misajon A, Zhang J, Jobling T, Quinn MA, Ostor AG, Nie G, Lopata A and Salamonsen LA: Presence of active gelatinases in endometrial carcinoma and correlation of matrix metalloproteinase expression with increasing tumor grade and invasion. Cancer 94: 1466-1475, 2002.
32. Poulsom R, Pignatelli M, Stetler-Stevenson WG, Liotta LA, Wright PA, Jeffery RE, Longcraft JM, Rogers L and Stamp WG: Stromal expression of 72 kDa type IV collagenase (MMP-2) and TIMP-2 mRNA in colorectal neoplasia. Am J Pathol 141: 389-396, 1992.
33. Poulsom R, Handy AM, Pignatelli M, Jeffery RE, Longcraft JM, Rogers L and Stamp GW: Expression of gelatinase A and TIMP-2 mRNAs in desmoplastic fibroblasts in both mammary carcinomas and basal cell carcinomas of the skin. J Clin Pathol 46: 429-436, 1993.
34. Ueno H, Nakamura H, Inoue M, Imai K, Noguchi M, Sato H, Seiki M and Okada Y: Expression and tissue localization of membrane-types 1, 2, and 3 matrix metalloproteinases in human invasive breast carcinomas. Cancer Res 57: 2055-2060, 1997.
35. Stamenkovic I: Matrix metalloproteinases in tumor invasion and metastasis. Semin Cancer Biol 10: 415-433, 2000.
36. Grignon DJ, Sakr W, Toth M, Ravery V, Angulo J, Shamsa F, Pontes JE, Crissman JC and Fridman R: High levels of tissue inhibitor of metalloproteinase-2 (TIMP-2) expression are associated with poor outcome in invasive bladder cancer. Cancer Res 56: 1654-1659, 1996.
37. Hernandez-Barrantes S, Bernardo M, Toth M and Fridman R: Regulation of membrane-type matrix metalloproteinases. Semin Cancer Biol 12: 131-8, 2002.